SCHEMBL30294444

SCHEMBL30294444

COC(=O)c1cc(C(F)(F)F)ccc1Nc1cc(F)c(F)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAS2R14 Q9NYV8 2/20 0.50
▸ CFTR P13569 1/20 0.50
▸ MRGPRX4 Q96LA9 2/20 0.42
▸ DHODH Q02127 1/20 0.41
▸ KDM4E B2RXH2 4/20 0.40
▸ HPGD P15428 2/20 0.40
▸ CES2 O00748 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ LIPC P11150 1/20 0.39
▸ LIPG Q9Y5X9 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ MCL1 Q07820 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.38
▸ MPO P05164 1/20 0.38
▸ AKR1C3 P42330 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22852770 1.00 TAS2R14 (0.50) TAS2R14CFTRMRGPRX4DHODHKDM4E
SCHEMBL29383454 0.87 CFTR (0.50) TAS2R14CFTRMRGPRX4DHODHMCL1
SCHEMBL22833864 0.87 CFTR (0.50) TAS2R14CFTRMRGPRX4DHODHMCL1
SCHEMBL22852835 0.87 TAS2R14 (0.62) TAS2R14MRGPRX4DHODHLIPCLIPG
SCHEMBL30294708 0.87 TAS2R14 (0.62) TAS2R14MRGPRX4DHODHLIPCLIPG
SCHEMBL26930895 0.85 CFTR (0.48) TAS2R14CFTRMRGPRX4KDM4EHPGD
SCHEMBL22853086 0.85 CFTR (0.50) TAS2R14CFTRMRGPRX4DHODHKDM4E
SCHEMBL22853395 0.84 DHODH (0.49) TAS2R14CFTRDHODHKDM4EHPGD
SCHEMBL30294511 0.84 DHODH (0.49) TAS2R14CFTRDHODHKDM4EHPGD
SCHEMBL22852810 0.82 CFTR (0.48) TAS2R14CFTRDHODHKDM4ECES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B TAS2R14 1406/4885CFTR 402/4885MRGPRX4 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback